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It has long been recognised that individuals vary in their susceptibility to
diseases and in their response to drugs, but it is only in the last 50 years
that progress has been made in elucidating the genetic basis of this
phenomenon. The term ‘pharmacogenetics’ was coined by Friedrich
Vogel in 1959 to denote the effects of polymorphisms within a particular
human gene on the disposition and action of drugs. Since the discovery
in the 1950s that the prolonged apnoea seen in some individuals after
administration of succinylcholine (a muscle relaxant) was due to an
inherited deficiency of the enzyme pseudocholinesterase,1 numerous
examples of polymorphisms in genes encoding drug-metabolising
enzymes, drug transporters and drug targets (enzymes, receptors) have
been described.2,3 Recent years have seen the first steps in translating
this information into clinical practice through the use of molecular
diagnostics (genotyping) to identify patients at risk of idiosyncratic drug
reactions.4 However, most drug effects are determined by the interplay
of multiple gene products, and polymorphisms in many genes may
affect the response to a specific drug. Technological advances allowing
the application of genome-wide approaches to identify the multiple
genetic polymorphisms that affect a drug response (pharmacogenomics)
hold out promise for the identification of disease-susceptibility genes
and genetic markers for drug efficacy, thereby opening the way for
personalised drug therapy.5
Clinical practice includes several notable examples of applied
pharmacogenetics, although prospective genetic screening remains to be
validated in randomised and adequately powered clinical trials. Licensing
authorities currently recommend the investigation of pharmacogenetic
associations, and genotyping information of relevance to drug safety is
increasingly appearing in prescribing information. This particularly applies
to drugs with narrow therapeutic indices, and several notable examples
are presented by cytostatics, oral anticoagulants and antiarrhythmics
metabolised by the polymorphic enzymes thiopurine S-methyltransferase
(TPMT), cytochrome P450 (CYP) 2C9 and CYP2D6. Genetic polymorphism
in these enzymes can variously result in abolished, reduced, altered or
enhanced activity, which is expressed as four major phenotypes: poor
metabolisers (lacking functional enzyme), intermediate metabolisers
(heterozygous for a defective allele), fast metabolisers (homozygous for
the functional allele) and ultra-rapid metabolisers (carrying >2 functional
gene copies).6 Genotyping for non-functional TPMT alleles is of value in
identifying patients at risk of potentially life-threatening myelosuppression
caused by thiopurines: in homozygous carriers of TPMT null mutations, 
6-mercaptopurine and azathioprine doses have to be reduced 10-fold or
more to avoid myelotoxicity.7 Other examples include CYP2C9 genotyping
for avoidance of warfarin-related haemorrhage and CYP2D6 genotyping
for optimisation of propafenone dosage.8,9
However, numerous obstacles impede progress in the practical
development of pharmacogenetics. Most clinically relevant genotype–
phenotype associations are polygenic effects, and genome-wide studies
require large sample sizes, involve complex statistical analyses and confer
a significant risk of generating false-positive associations.
Genetic Polymorphism 
Analysis of the human genome indicates that there are several forms 
of genetic variation, including nucleotide deletions, insertions,
oligonucleotide repeats and single nucleotide polymorphisms (SNPs) –
stable, discrete, single-nucleotide substitutions that occur in ≥1% of the
population (lower-frequency variations are considered mutations).10 Inter-
individual differences in human DNA sequence are predominantly the
result of SNPs. These sequence alterations, which occur every 100–300
bases along the three-billion base pairs in the human genome,11 may
have a variety of effects: non-synonymous SNPs within coding regions
alter the amino acid sequence of the encoded protein; SNPs within the
promoter region may affect the transcription of a gene; and SNPs within
the 3’ untranslated region following the coding sequence may affect the
intracellular stability of the mRNA transcript. Moreover, not all individual
changes in DNA sequence (genotype) have an effect on gene expression
(phenotype). Most genes or groups of genes on a segment of a
chromosome contain multiple SNPs that have been inherited together,
and these polymorphisms therefore appear in specific blocks or patterns,
known as haplotypes. The number of haplotypes for a gene or segment
of a chromosome is generally considerably smaller than the total possible
number of SNP combinations within that block. In addition to reducing
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the number of variables that need to be examined for association with
drug response, haplotypes provide a more accurate prediction of gene
activity since they reflect the sum of the effects of individual SNPs. 
Rationale for the Application of Pharmacogenetics to 
HIV Therapeutics
Since the introduction of zidovudine in 1987, more than 20
antiretroviral drugs targeting HIV reverse transcriptase, protease and
viral entry have been licensed for the treatment of HIV/AIDS. The use of
these agents is associated with considerable inter-individual variability
in plasma drug exposure, antiretroviral efficacy and tolerability.12
Factors affecting variability in plasma drug exposure include host
genetics, underlying disease, patient compliance, co-medication and
demographic factors such as age, gender and race. Host sources of
variability in antiretroviral efficacy and tolerability include both
immunogenetic factors (HLA/immune response genes) and
pharmacogenetic factors (drug-metabolising enzyme and drug
transporter and drug receptor genes).13–15
Pharmacogenetic Factors and Drug Response
Many antiretroviral agents have a predominant metabolic pathway and a
narrow therapeutic index, and the HIV therapy area is particularly well suited
to pharmacogenetic investigation. Important factors underlying the marked
pharmacokinetic variability of antiretroviral drugs include their dependence
on intracellular phosphorylation for generation of the active drug moiety
(nucleoside reverse transcriptase inhibitors – NRTIs) and their role as
substrates of genetically polymorphic drug-metabolising enzymes and
transporters (protease inhibitors – PIs – and non-nucleoside reverse
transcriptase inhibitors – NNRTIs). Prominent among this latter category are
the phase I oxidative enzymes of the CYP450 family, phase II conjugative
enzymes and drug transporters such as P-glycoprotein, the multidrug
transporter multidrug resistance (MDR1) gene product.3,13,16,17 Numerous
genetic polymorphisms in the CYP450 family – most notably the CYP3A,
CYP2C19/9 and CYP2D6 isoforms – influence drug metabolism, resulting in
altered plasma drug exposure.6,17 CYP450 polymorphisms with potential
relevance to antiretroviral therapy include CYP3A4 (PI), CYP3A5 (indinavir,
saquinavir), CYP2C19 (nelfinavir) and CYP2B6 (efavirenz, nevirapine).14,18–22
Among the drug conjugation enzymes, polymorphisms in uridine
diphosphate glucuronosyl transferase 1A1 (UGT1A1), which catalyses
drug–bilirubin conjugation reactions,23 have implications for antiretroviral
toxicity (atazanavir and indinavir).19,24
Transporter proteins – of which the best characterised are the 
adenosine triphosphate (ATP)-binding cassette proteins, which include 
P-glycoprotein (MDR1, ABC1) and the multidrug-resistance proteins
(MRP-1–9) – have largely evolved to protect the host from potentially
toxic substances. All of the current PIs are substrates for the 
P-glycoprotein efflux pump in the small intestine,25 and polymorphisms in
the multidrug transporter MDR1 gene encoding P-glycoprotein may have
significant implications for protease inhibitor exposure, efficacy and
toxicity.26 Polymorphisms in drug transporters with potential relevance to
antiretroviral therapy include P-glycoprotein (PIs, zidovudine, nevirapine)
and organic anion transporters (OATs) (tenofovir).22,25,27–29 
Immunogenetic Factors and Drug Safety
Genetic factors have long been postulated to be important in drug
hypersensitivity reactions, which can be regarded as inappropriate
immune responses resulting in tissue damage from otherwise non-toxic
agents. Investigation has largely focused on genes encoding for immune
responsiveness, including major histocompatability complex (MHC), 
T-cell receptor and co-stimulatory molecules.30 In the case of
antiretroviral agents, evidence suggests that, in Caucasian populations,
immunogenetic factors (human leukocyte antigen (HLA) haplotype)
and/or immunological factors (CD4+ lymphocyte count) are important
determinants of susceptibility to hypersensitivity reactions to abacavir
and nevirapine.31-35 
Clinical Relevance of Genetic Polymorphism in the
Treatment of HIV Infection 
In the clinical setting, the use of polypharmacy and combination therapy
makes it difficult to establish the relationship, if any, between host-
specific response factors and individual drugs, and greatly complicates
attempts to establish the broad clinical utility of screening for the relevant
markers as an aid to drug selection. At the same time, polypharmacy and
combination therapy increase the risk of drug-specific adverse events. In
contrast to host-specific response factors, the influence of host-specific
toxicity factors for an individual drug are unlikely to be masked by the
presence of co-administered agents.
Currently, the most promising application of pharmacogenetics to the
field of HIV medicine, and one that readily lends itself to clinical
investigation of its utility as a patient-management tool, is the
identification of those individuals at greatest risk of genetically influenced
drug toxicities. Potential genotypic–phenotypic correlations for drug-
associated adverse events, or potential mechanisms for such events, have
been elucidated for several antiretroviral agents, including nevirapine,
atazanavir, efavirenz, tenofovir and abacavir.
Nevirapine-associated Hypersensitivity
Nevirapine-associated hypersensitivity, which is characterised by fever
with rash or hepatitis during the first six weeks of treatment, affects an
estimated 5% of HIV-infected patients.34 Post-marketing surveillance
indicates that nevirapine-associated hepatitis and rash are more common
in women and those without HIV infection, as well as in men with CD4+
cell counts ≥400 cells/µl (odds ratio 3) and women with CD4+ counts
≥250 cells/µl (odds ratio 12).36 Accordingly, high rates of nevirapine
hypersensitivity are observed in HIV-negative individuals receiving
nevirapine prophylactically.37 Results from an Australian cohort study
suggest that early hepatitis and hepatitis-associated rash with nevirapine
have a strong immunogenetic basis, with HIV-infected patients exhibiting
the HLA class II allele HLA-DRB1*0101 and CD4+ cell counts >25%
Table 1: Contribution of Combined Individual Loci of 57.1
Haplotype to Susceptibility to Abacavir Hypersensitivity
HLA Type Abacavir- Abacavir-tolerant  Odds Ratio P-value
hypersensitive (n=167) (95%  CI)
(n=18)
HLA-B*5701 14 (78%) 4 (2%) 117  <0.0001
(29–481)
HLA-DR7,  13 (72%) 6 (3%) 73  <0.0001
HLA-DQ3 (20–268)
HLA-B*5701;  13 (72%) 0 (0%) 822 <0.0001
HLA-DR7, (43–15675)
HLA-DQ3
HLA: human leukocyte antigen; CI: confidence interval.
Reproduced from Winston et al. 2006.81
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having a 17-fold increased risk of developing these symptoms.35 This
would suggest that HLA type may be a prerequisite, but is insufficient in
itself, for development of nevirapine hypersensitivity, and that the
reaction is attenuated by a low CD4+ cell count. Recent data from a
Mediterranean (Sardinian) population indicate that the HLA class I allele
HLA-Cw8-B14 is additionally associated with hypersensitivity to
nevirapine.38,39 Moreover, nevirapine-related hypersensitivity appears to
be susceptible to MDR1 gene polymorphism, with MDR1 3435 CT or TT
genotypes conferring a significantly lower risk of hepatotoxicity than the
CC genotype.40,41
Atazanavir- and Indinavir-related 
Hyperbilirubinaemia and Jaundice
Unconjugated hyperbilirubinaemia affects ~20–50% of atazanavir- and
5–25% of indinavir-treated patients, and ~6% of patients show overt
clinical jaundice.42,43 This effect is attributable to competitive inhibition by
atazanavir and indinavir of uridine diphosphate glucuronosyl transferase
1A1 (UGT1A1)-mediated bilirubin conjugation and clearance.44 This adverse
metabolic event is much more common in the 5–10% of the population
with Gilbert’s syndrome, who have an underlying genetic defect in bilirubin
conjugation. Gilbert’s syndrome is caused by a polymorphism in the
promoter TATA region of the gene encoding UGT1A1, with the
UGT1A1*28 allele resulting in reduced enzyme activity and asymptomatic
hyperbilirubinaemia.19,24,45 In these patients, the incidence of atazanavir- or
indinavir-associated hyperbilirubinaemia varies according to UGT1A1
promoter genotype, ranging from ~15% in those with the wild-type allele
to 90% in those homozygous for the UGT1A1*28 allele; this latter group is
more likely to experience bilirubin levels within the clinical jaundice range
(>2.5mg/dl).19 It is unclear, however, whether this drug-associated
hyperbilirubinaemia is linked exclusively to functional polymorphism in
UGT1A1: UGT1A1*28 forms part of a haplotype of four UGT1A variants
(UGT1A1*28, UGT1A3-66C, UGT1A7-57G and UGT1A7129K/131K)
spanning three genes at the UGT1A gene locus that predisposes to
hyperbilirubinaemia with atazanavir.46 In addition, a polymorphism in the
MDR1 gene (3435C>T) appears to result in increased plasma atazanavir
exposure and elevated plasma bilirubin levels.29
Efavirenz-related Neurotoxicity
Efavirenz is extensively metabolised by CYP2B6,47 a genetically
polymorphic enzyme,48 and displays marked inter-individual and inter-
racial variability in both its pharmacokinetics and incidence of
neurotoxicity.49,50 The CYP2B6 516G>T polymorphism – which occurs
more frequently in African-Americans than in Caucasians (20% versus
3%, respectively, have the 516T/T genotype)51 – is associated with
increased plasma efavirenz exposure and a higher incidence of adverse
central nervous system (CNS) effects during initial treatment.18,51,52 In
addition, individuals homozygous for the CYP2B6*6 allele, which
contains both the 516G>T and 785A>G polymorphisms, show
significantly higher plasma efavirenz levels than heterozygous individuals
or those without the CYP2B6*6 allele.53 Likewise, the CYP2B6*16 allele,
which contains the 983T>C and 785A>G polymorphisms, is associated
with elevated plasma efavirenz levels.54
Nucleoside Reverse Transcriptase Inhibitor-related
Lipodystrophy and Peripheral Neuropathy
Lipodystrophy (subcutaneous fat wasting) and peripheral neuropathy are
manifestations of mitochondrial toxicity associated with NRTIs, most
notably the thymidine analogues stavudine, zidovudine and didanosine.55
The risk and subsequent severity of NRTI-related lipodystrophy is affected
by host factors such as age, race (it is more common in Caucasians) and
level of immune competence, suggesting a possible underlying genetic
mechanism.56 In Caucasians, susceptibility to NRTI-associated
lipodystrophy has been linked to a promoter polymorphism in the tumour
necrosis factor (TNF)-α gene (TNF-238A).57,58 This may represent an
important pathophysiological association, as TNF appears to regulate
mitochondrial apoptosis.59 Also in Caucasians, susceptibility to stavudine-
and didanosine-related peripheral neuropathy has been associated with
polymorphisms in the mitochondrial genome, in particular with the
mitochondrial haplogroup T.60
Ritonavir-associated Hyperglyceridaemia
The use of protease inhibitors, in particular ritonavir, in HIV-infected patients
is frequently associated with atherogenic lipid abnormalities, including
increased plasma triglyceride, high-density-lipoprotein cholesterol and
apolipoprotein B levels,61 and there is marked racial variability in
susceptibility to antiretroviral drug-induced hyperglyceridaemia.62
Polymorphism in the genes encoding apolipoproteins E and C3 (APOE,
APOC3) and the promoter region of the TNF-α gene have been linked to
development of dyslipidaemia with protease inhibitors. The presence of
variant APOC3 (455 T/C, 482 C/T, Sstl) and APOE (ε2, ε4) alleles has been
associated with increased risk of severe hyperglyceridaemia in Caucasian
patients on protease inhibitor-containing highly active antiretroviral therapy
(HAART) regimens,63,64 whereas variant APOC3 (455 T/C, 482 C/T, Intron 1
G/C) alleles appear to confer protection against hypertriglyceridaemia in
Hispanic patients.62
Tenofovir-related Renal Proximal Tubulopathy
Renal proximal tubulopathy – manifest as acidosis, glycosuria and
proteinuria – has been described during long-term tenofovir therapy in
HIV-infected patients.65 This renal cytotoxicity has been associated with a
polymorphism (1249G>A) in the ABCC2 gene encoding the MRP2
transporter.66 ABCC2 haplotype also appears to influence susceptibility to
tenofovir-induced renal proximal tubulopathy, with CATC functioning as
a predisposing haplotype and CGAC as a protective haplotype.66 In
addition, tenofovir (in common with adefovir and cidofovir) is a substrate
of the renal OAT-1.67 The R50H genetic variant of OAT-1, which appears
to be confined to Africans, shows substantially enhanced binding with
tenofovir,68 suggesting that those individuals carrying the R50H
polymorphism in OAT-1 have altered tenofovir handling.   
Abacavir-related Hypersensitivity
Abacavir therapy is limited by idiosyncratic hypersensitivity reactions
characterised by fever, rash and gastrointestinal symptoms that usually
appear within the first six weeks of treatment.69 These affect ~8% of
patients,32 although symptoms are non-specific and can be difficult to
distinguish from those of concomitant viral illness and/or similar reactions
to concomitant antiretrovirals, other drugs or inflammatory disease.70 The
Table 2: Factors Favouring Implementation of Pharmacogenetic
Testing in Clinical Practice 
• Ready availability of a rapid, low-cost pharmacogenetic test
• High predictive value
• Ease of incorporation into routine patient management
• Identification of clinical parameters that determine usefulness
• Clinical outcome affects the wellbeing of patients
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2–3% false-positive rate for diagnosis of clinical hypersensitivity to
abacavir71–73 means that the true incidence is closer to 5%. The syndrome
is reversed on abacavir discontinuation, but abacavir rechallenge can
result in rapid onset of life-threatening hypotension.74 A genetic
component of the syndrome was originally suggested by reports of a
familial association75 and a lower incidence in men and individuals of
African origin.76 In Caucasians, abacavir hypersensitivity has been linked
with HLA markers, with the HLA-B*5701 allele being most strongly
implicated.31,77,78 Recombinant mapping of other alleles on the 57.1
ancestral haplotype, as well as the presence of HLA-B*5701 in abacavir-
tolerant individuals, suggests that HLA-B*5701 is necessary but not
sufficient by itself for causing abacavir hypersensitivity.32,79 Estimates of
the sensitivity of HLA-B*5701 as a predictor of abacavir hypersensitivity
in this ethnic group range from 48 to 94%.32,78,80 In contrast, the
association between HLA-B*5701 genotype and abacavir hypersensitivity
appears to be appreciably weaker in individuals of African origin,33,78
although, as with the variable strength of association noted in
Caucasians, it is currently unclear whether this is a true effect or a
consequence of the difficulty of accurate clinical phenotyping. A
retrospective analysis of 595 cases of suspected abacavir hypersensitivity
indicated that no combination of markers offered superior predictive
sensitivity or specificity to HLA-B*5701 alone (50% and 98%,
respectively) among Caucasians.78 However, early studies have been
limited by their retrospective design, as well as by problems in defining
precisely the phenotype of the abacavir hypersensitivity reaction. Results
from an Australian cohort indicated that the HLA-B*5701, HLA-DR7 and
HLA-DQ3 haplotype had a positive predictive value of 100% and a
negative predictive value of 97% for abacavir hypersensitivity (see Table
1).31,81 Recombinant haplotype mapping has also implicated a variant
allele within the heat-shock protein family (Hsp70 Hom M493T), which is
carried on the ancestral 57.1 haplotype, as being important in abacavir
hypersensitivity,32 with the HLA-B*5701 and Hsp70 Hom M493T
combination occurring in >90% of the abacavir-hypersensitivity patients
compared with fewer than 0.4% of abacavir-tolerant individuals.32
Challenges for Translating Pharmacogenetic Research into
Routine Patient Management
The application of pharmacogenetics to clinical practice is complicated by
the lack, in most instances, of a robust and uniform correlation between
single polymorphisms and plasma drug exposure, drug efficacy and/or
tolerability. Factors determining the successful implementation of
pharmacogenetic testing in clinical practice are summarised in Table 2.
Pharmacogenetic associations are typically derived from small or stratified
population samples, and their applicability to the broader population and
diverse ethnic groups is unclear. The sensitivity and specificity of a
pharmacogenetic association is likely to vary from study to study because
of these factors, raising uncertainty about the clinical utility of routinely
screening for the marker in question. Despite the previously described
established associations between specific polymorphisms and drug safety
outcomes, most come with challenges for their potential implementation
as patient-management tools.
HLA-DRB1*0101 Screening for Nevirapine Hypersensitivity
The presence of the HLA class II allele HLA-DRB1*0101 in conjunction with
CD4+ cell count >25% has been associated with a markedly increased (17-
fold) risk of nevirapine-related hepatitis and rash in Caucasian patients,
suggesting that this allele may serve as an immunogenetic marker for
nevirapine hypersensitivity.35 However, the recent identification of a
different allelic marker (HLA-Cw8) in at least some populations38,39 may
complicate efforts to establish the utility of a universal prognostic marker.
UGT1A1*28 Screening for Atazanavir-/Indinavir-related
Hyperbilirubinaemia and Jaundice
Prospective UGT1A1*28 genotyping has been proposed for identifying
patients at risk of atazanavir/indinavir-related hyperbilirubinaemia and
jaundice.19 However, the influence of the P-glycoprotein 3435C>T
polymorphism on plasma atazanavir exposure and plasma bilirubin levels29
introduces a potential second mechanism that requires separate assessment. 
CYP2B6 Genotyping for Efavirenz-related Neurotoxicity
The high degree of overlap between CYP2B6 genotypes and the multiplicity
of factors affecting efavirenz exposure are likely to limit the value of CYP2B6
genotyping in identifying patients at risk of efavirenz-related neurotoxicity.82
MRP2 Genotyping for Tenofovir-related Renal 
Proximal Tubulopathy
The practical value of screening for the 1249G>A polymorphism in the
MRP2 transporter as a means of identifying patients at risk of tenofovir-
related renal tubulopathy is uncertain, given the relatively low sensitivity
of this marker (41% of cases versus 17% of tolerant controls).66
Additionally, the potential for a racially stratified second
pathophysiological mechanism (hOAT-1 transport) underlying tenofovir-
mediated renal cytotoxicity may complicate matters.66,68
HLA-B*5701 Screening for Predisposition to 
Abacavir Hypersensitivity
HLA-B*5701 is the most extensively studied pharmacogenetic marker in
HIV therapeutics, and HLA-B*5701 screening for predisposition to abacavir
hypersensitivity is currently the most clinically promising pharmacogenetic
intervention for improving patient safety. Observational findings suggest
that prospective HLA-B*5701 genotyping and subsequent avoidance of
abacavir use in HLA-B*5701-positive patients can reduce the incidence of
hypersensitivity reactions to less than 2% in Caucasian populations.83–85
Moreover, HLA-B*5701 genotyping appears to be a cost-effective strategy
in this population: results based on a meta-analysis of three cohorts
showed that to prevent one case of hypersensitivity, eight HLA-B*5701-
positive patients would be denied abacavir and that, to identify them, 48
patients would require testing.80 HIV clinics in some centres now routinely
screen patients for HLA-B*5701,86 although the benefits of universal
screening, particularly in non-Caucasian populations, are unclear:
preliminary evidence suggests that the predictive sensitivity of the HLA-
B*5701 test is appreciably lower in Hispanic and Black than in Caucasian
populations,78 although this may be an artefact of case ascertainment. For
prospective HLA-B*5701 screening to realise its full potential, it will be
necessary to establish the degree of association in non-Caucasians using
Pharmacogenetic associations are
typically derived from small or
stratified population samples, and their
applicability to the broader population
and diverse ethnic groups is unclear.
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large-scale, well-powered prospective studies in geographically and
ethnically diverse HIV-patient populations. These data will hopefully be
provided by the European Prospective Randomised Evaluation of DNA
Screening In a Clinical Trial (PREDICT-1) (Study CNA106030;
clinicaltrials.gov ID NCT00340080) and the US Study of Hypersensitivity to
Abacavir and Pharmacogenetic Evaluation (SHAPE) (Study ABC107442,
clinicaltrials.gov ID NCT00373945) trials, which are now completed and
due to report later this year. PREDICT-1 is a randomised, double-blind study
designed to assess the impact of HLA-B*5701 screening on the incidence
of abacavir hypersensitivity in ~2,000 abacavir-naïve adults with HIV
infection. Hypersensitivity rates, with and without case refinement by
epicutaneous abacavir patch testing,87,88 will be compared between two
groups of patients with a pre-existing clinical need for de novo abacavir
therapy: a non-screening (current standard-of-care) arm whose HLA-
B*5701 status was evaluated retrospectively at study end and a prospective
genetic screening arm in which subjects testing positive for carriage of
HLA-B*5701 were excluded from receiving abacavir in the study.
Investigators and patients remained blinded to which arm patients
receiving abacavir were randomised. As such, it is the first controlled,
blinded, randomised prospective study undertaken with the statistical
power to determine the clinical utility of screening for a specific
pharmacogenetic marker. 
SHAPE is a retrospective case-control study designed to evaluate the
performance characteristics of HLA-B*5701 as a marker for abacavir
hypersensitivity in Caucasian and African-Americans, using epicutaneous
patch testing as a tool of case refinement. The study will include
approximately 600 HIV-infected adults (approximately 200 with suspected
or patch-test-confirmed abacavir hypersensitivity and approximately 200
abacavir-tolerant controls for each racial group), and will estimate the
sensitivity/specificity of the HLA-B*5701 marker in each ethnic group.  
The feasibility of widespread application of HLA-B*5701 genotyping in the
clinical setting will depend not only on the outcomes of the PREDICT-1 and
SHAPE studies, but will also be materially assisted by the development and
introduction of validated high-throughput screening methods for HLA-
B*5701, such as sequence-specific amplification or flow cytometry.89,90
Conclusions
Pharmacogenetics provides scope for a more informed and individualised
treatment approach to HIV, using information about host genetic
variability to optimise antiretroviral drug efficacy, safety and longevity of
therapy. This is likely to become an increasingly important area of study as
the diversity of the treatment population expands and pharmacogenetic
research in developing countries adds to the state of knowledge.
Moreover, the field of pharmacogenetics is likely to provide further insight
into our understanding of the pathophysiology and evolution of disease.
However, success in translating pharmacogenetic knowledge into clinical
practice has been limited to date, and a number of factors complicate
attempts to establish the applicability and utility of pharmacogenetics in
the general patient population. Of the various pharmacogenetic
associations noted in the field of HIV therapeutics, those relating to drug-
specific adverse events are the most clear-cut and convincing. However,
even here, confounding factors reflecting the polygenic nature of the
event, the use of small or stratified sample populations, and the moderate
and/or variable levels of pharmacogenetic association typically reported
have impeded progress in implementing standard-of-care genetic
screening for identifying patients at risk of antiretroviral drug toxicity.
Realisation of the full potential of pharmacogenetics in the clinic will
require attention to appropriate phenotypic definitions, completion of
large-scale, well-controlled prospective studies and the introduction 
of novel laboratory technologies. Such studies are currently underway to
investigate the utility of HLA-B*5701 as a genetic marker for
predisposition to abacavir hypersensitivity, and this will be the first
pharmacogenetic association for which definitive data applicable to
routine clinical practice will be available. However, there are other
pharmacogenetic associations, particularly those relating to drug safety, in
HIV and other therapy fields that would similarly benefit from a rigorous
investigation of genotype-guided drug selection. ■
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